Tag Archives: FDA

NIH Announces New Initiative to Speed Up COVID-19 Diagnostics Development

The National Institutes of Health has launched a new initiative to accelerate the development and commercialization of testing technologies for the new coronavirus. The Rapid Acceleration of Diagnostics program will use $1.5B in federal stimulus funds to invest in efforts that work on new COVID-19 testing technologies, NIH said Thursday.

Read More »

Health Agencies, Biopharmaceutical Firms Form Partnership to Accelerate COVID-19 Vaccine Development

health-agencies-biopharmaceutical-firms-form-partnership-to-accelerate-covid-19-vaccine-development

The National Institutes of Health and three other U.S. health agencies have teamed up with the Foundation for the NIH, European Medicines Agency and 16 biopharmaceutical companies to speed up the development of vaccines and treatments for COVID-19. The Accelerating COVID-19 Therapeutic Interventions and Vaccines partnership will work to streamline clinical trials, coordinate regulatory processes and use assets to accelerate response to the coronavirus pandemic and other future health emergencies, NIH said Friday.

Read More »

FDA Continues COVID-19 Treatment R&D; Stephen Hahn Quoted

fda-continues-covid-19-treatment-rd-stephen-hahn-quoted

The Food and Drug Administration (FDA) has responded to the COVID-19 pandemic by facilitating medical countermeasures to treat and prevent the disease and surveilling the medical product and food supply chains for potential shortages or disruptions and helping to mitigate impacts, the FDA reported Friday.

Read More »

Weekly Roundup: Leidos Buys IMX, Executive Moves, POC Hosting 2019 Security Vetting Process Modernization Forum Update on Aug. 14th & Weekly Top 10 Stories

Leidos agreed to purchase IMX Medical Management Services, a consulting firm that offers independent medical evaluation, case management and record review services to state and local government agencies. The terms of the deal were not disclosed, but the company expects to close the transaction in the third quarter, pending customary approvals. In …

Read More »